Back to Journals » Neuropsychiatric Disease and Treatment » Volume 12

Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity

Authors Santamato A

Received 7 November 2015

Accepted for publication 30 December 2015

Published 27 January 2016 Volume 2016:12 Pages 251—263

DOI https://doi.org/10.2147/NDT.S86978

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Xiang Mou

Peer reviewer comments 3

Editor who approved publication: Dr Roger Pinder


Video abstract presented by Dr Sarma and Dr Brophy.

Views: 182

Andrea Santamato

Physical Medicine and Rehabilitation Section, “OORR Hospital,” University of Foggia, Foggia, Italy

Abstract: Spasticity is a common disabling symptom for several neurological conditions. Botulinum toxin type A injection represents the gold standard treatment for focal spasticity after stroke showing efficacy, reversibility, and low prevalence of complications. In recent years, incobotulinumtoxinA, a new Botulinum toxin type A free of complexing proteins, has been used for treating several movement disorders with safety and efficacy. IncobotulinumtoxinA is currently approved for treating spasticity of the upper limb in stroke survivors, even if several studies described the use also in lower limb muscles. In the present review article, we examine the safety and effectiveness of incobotulinumtoxinA for the treatment of spasticity after stroke.

Keywords: Hypertone, botulinum toxin, incobotulinumtoxinA, onabotulinumtoxinA, abobotulinumtoxinA

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]